Antihistamines Don't Really Lose Their Punch. Sprays Do.
The idea that Zyrtec or Claritin "stops working" after enough years is mostly folklore. The medicine that genuinely does lose its effect is the decongestant spray sitting next to it.
Someone has taken the same allergy pill every March for a decade. This spring, it barely dents the sneezing. The instinct is to blame the drug: the body got used to it, so it must be time to switch. That explanation circulates constantly in allergy forums and pharmacy blog posts. It is also, according to the pharmacology of modern antihistamines, usually the wrong one.
True tachyphylaxis, a genuine, receptor-level drop in a drug's effect with repeated use, is well documented for one specific category of allergy product: over-the-counter decongestant nasal sprays such as oxymetazoline, sold as Afrin and a long list of store brands. It is not well proven for the oral antihistamines most people reach for first: cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra), or the older diphenhydramine (Benadryl). Conflating the two is the root of a lot of unnecessary medication-swapping.
Can you build a tolerance to Claritin or Zyrtec?
Second-generation antihistamines work by competitively blocking histamine H1 receptors: they occupy the docking site histamine would otherwise use, rather than reprogramming the receptor itself. That mechanism matters, because true tachyphylaxis usually involves the receptor becoming less sensitive or less available over time. A guide published by Bolt Pharmacy, drawing on NICE, BSACI and MHRA guidance, is blunt about it: cetirizine and loratadine "do not cause tachyphylaxis — the body does not develop true tolerance to their effects." A controlled study cited in that review found no meaningful drop in loratadine's effect on skin and allergen testing over 12 weeks; a separate trial found no tachyphylaxis for 10 mg cetirizine or 5 mg levocetirizine across 180 days of daily use.
None of the major prescribing bodies (not NICE, not the UK's British Society for Allergy and Clinical Immunology, not the MHRA) recommends rotating antihistamines to "reset" their effect. There simply isn't a clinical basis for it. That doesn't mean everyone responds identically. Genetic variation in the liver enzymes that clear these drugs can change how long an individual dose lasts, and fexofenadine absorption drops when it's taken with fruit juice or aluminum-containing antacids, a real pharmacokinetic quirk, not tolerance. First-generation diphenhydramine is its own case study in unpredictable individual response; Daybreak Wire has covered why it makes some people wired instead of drowsy, a reminder that antihistamines don't behave the same way in every body.
So why does it feel like the pills quit?
A few things, and none of them require the drug to have failed. Pollen counts spike and fall through a season; a dose that handled April's tree pollen may be overmatched by June's grass pollen, which is a change in exposure, not in the drug. New sensitivities can also develop with age, shifting what triggers symptoms in the first place. Then there's plain adherence: taking a pill only after symptoms are already severe works far worse than taking it on a steady daily schedule through the season, and for nasal sprays specifically, technique errors, such as aiming toward the septum instead of the outer wall of the nostril, blunt the dose that actually reaches the tissue.
Placebo and nocebo effects are real too. Expecting a medication to fail can make its relief feel thinner than it is. None of this is a reason to dismiss a reader's frustration. It is a reason to check the boring variables (timing, dose, technique, exposure) before assuming biology has turned against a drug that, by the evidence, mostly hasn't.
Why decongestant nasal sprays actually do stop working
Here the pharmacology is different, and the warning is not folklore. Oxymetazoline and its relatives (xylometazoline, naphazoline) constrict blood vessels in the nasal lining through adrenergic receptors rather than blocking histamine. According to a StatPearls clinical review updated in March 2026, one leading hypothesis for what happens next is genuine tachyphylaxis: the adrenoreceptors become refractory to the drug, needing higher and more frequent doses to achieve the same effect, while sympathetic nerve signaling that normally keeps blood vessels constricted gets suppressed by negative feedback. When the spray wears off, the vessels swell back, often worse than before.
Older ephedrine-based decongestants could trigger this rebound as early as three days in and as late as four to six weeks; with today's imidazoline sprays like oxymetazoline, StatPearls notes the risk is somewhat lower but "remains clinically significant with prolonged or inappropriate use," typically emerging after five to seven days. U.S. product labeling doesn't wait that long to warn people off: Cleveland Clinic's guidance on oxymetazoline states plainly that using it for longer than three days may lead to rebound congestion, and instructs patients not to use it more than three days in a row without medical advice.
| Medication type | True pharmacological tolerance? | What the evidence shows |
|---|---|---|
| Oral antihistamines (cetirizine, loratadine, fexofenadine) | Not established | Block H1 receptors competitively; 12- to 180-day trials found no meaningful drop in effect |
| Topical decongestant sprays (oxymetazoline, xylometazoline) | Well documented | Rebound congestion can begin within days; labeling caps continuous use at three days |
The condition has a name, rhinitis medicamentosa, and it isn't rare. Once it sets in, congestion doesn't fade on its own the way a cold does; discontinuing the spray is the actual treatment, and symptoms typically get worse before they get better. StatPearls notes that subjective rebound symptoms can resolve within 48 hours when an intranasal corticosteroid is started alongside quitting the decongestant, versus more than a week with no treatment at all. The physical swelling and inflammation in the nasal lining take longer to settle, often seven to fourteen days.
When to actually switch or see an allergist
The practical guidance splits cleanly along the line the pharmacology draws. Decongestant sprays should never be used for more than three days running, full stop, regardless of how congested the underlying problem feels. Once rebound congestion has set in, a short course of a nasal steroid spray during withdrawal, not another round of the decongestant, is what actually resolves it. Anyone who has been reaching for the same over-the-counter spray on and off for weeks rather than days has a real reason to talk to a pharmacist or physician, not just a habit to break unassisted.
For oral antihistamines, the more useful move before assuming tolerance is a plain audit: is the dose being taken daily and on schedule through the season, not just when symptoms flare? Is it fexofenadine taken too close to a glass of orange juice? Has this spring's pollen count actually been unusually high? If those checks come back clean and symptoms are still poorly controlled, switching to a different antihistamine, or adding an intranasal corticosteroid, is reasonable: that reflects differences in individual receptor binding and absorption at work, not the body defeating the drug. Persistent, poorly controlled symptoms despite a careful regimen are also the point at which an allergist becomes worth the referral: skin or blood testing can identify what's actually driving the reaction, and options like allergen immunotherapy address the underlying sensitivity rather than chasing symptom relief drug by drug.
The reassurance and the caution point in different directions on purpose. Most people whose allergy pills feel weaker haven't been failed by their own biology; they've been failed by pollen counts, timing, or a spray they should have put down after day three.
